60699-67-4

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 3086-29-1 trimethylsulfonium chloride 
• 17694-68-7 3-(2-bromoacetyl)pyridine hydrobromide 
• 118838-57-6 (1-R)-2-bromo-1-(3-pyridinyl)-1-ethanol 
• 2181-42-2 trimethylsulphonium iodide 
• 2181-44-4 trimethylsulfonium methylsulfate 

Downstream Products

• 329281-07-4 (S)-3-(2-oxiranyl)pyridine 
• 40594-83-0 1-pyridin-3-yl-ethane-1,2-diol 
• 793652-84-3 4'-(2-{[2-hydroxy-2-(3-pyridyl)ethyl]amino}ethyl)-2-(2-pyridyl)acetanilide 
• 91800-29-2 2-(propylamino)-1-(pyridin-3-yl)ethan-1-ol 

Relevant academic research and scientific papers

AZEPINO [4, 5-B] INDOLES AND METHODS OF USE

This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1, 2,3,4,5, 6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES

This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

HETEROCYCLIC COMPOUNDS

The invention is related to novel substituted diazaheterocycles useful as effective antihypercholesterolemic agents, methods of their preparation, and pharmaceutical compositions containing them.

NOVEL DERIVATIVES OF PYRIDYLETHANOL (PHENYLETHYL) AMINES AS INHIBITORS OF CHOLESTEROL BIOSYNTHESIS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The novel derivatives of pyridylethanol (phenylethyl) amines of formula I are described wherein n is an integer from 1 to 4, R1 is a hydrogen atom, hydroxyl group or lower C1-6 alkoxy group R2 is a hydrogen atom or a straight or branched lower C1-6 alkyl group X, is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-CI,2,4-di-CI or lower C1-6 alkoxy group, the enantiomers, diastereoisomers or racemates thereof or the physiologically acceptable acid addition salts thereof which are ligands of sigma receptors for inhibiting cholesterol biosynthesis and are thus appropriate for the treatment of hypercholesterolemia and hyperlipemia in humans. The greatest lowering of cholesterol was observed by 1-(d-pyridyl)-2-(N-(2-(3,4-dicholorophenyl)ethyl-N-propylamino)ethanol in the form of dihydrobromide salt (signature BK-35. 2HBr).

5- substituted tetralones as inhibitors of ras farnesyl trransferase

The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.

Studies on cognitive enhancing agents. II. Antiamnestic and antihypoxic activities of 1-aryl-2-(2-aminoethoxy)ethanols

A series of 2-(2-aminoethoxy)-1-phenylethanols having a variety of N- and phenyl-substitution patterns as well as 5- and 6-membered heteroaryl counterparts of our prototype compound 1 (2-(2-dimethylaminoethoxy)-1- phenylethanol) have been prepared and evaluated for antiamnestic and antihypoxic activities. Compound 3b, the 3-methylphenyl analogue of 1, proved to be significantly more potent than I in reversing electroconvulsive shock- induced amnesia as well as CO2-induced learning-impairment in mice. It exhibited low acute toxicity in mice and afforded a greater brain/serum concentration ratio than 1 after oral administration to rats.

β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives

β-Adrenergic receptor site activation by novel pyridinemethanol derivatives and pharmaceutical compositions and methods of use thereof are described.

A NOVEL APPROACH TO FUNCTIONALIZATION OF AZINES. OXIRANYL AND THIIRANYL DERIVATIVES OF PYRIDINE, QUINOLINE AND ISOQUINOLINE

Convenient methods for synthesis of the oxiranyl and thiiranyl derivatives of pyridine, quinoline and isoquinoline have been elaborated.Oxiranes have been synthesized from corresponding aldehydes with dimethylsulfonium methylide in anhydrous medium.Exchange of the oxygen atom in the oxirane ring on sulfur with potassium thiocyanate gave thiiranylazines.